AI Multi-Omics Analytics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 2.5 billion
Estimated Base Value
2035 Forecast
US$ 19.4 billion
Projected Market Value
CAGR 2026–2035
22.7%
Compound Annual Growth
Largest Segment
AI-powered Multi-Omics Software Platforms
Fastest Growing Segment
AI-Enabled Multi-Omics Data Integration Tools
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
32.0% market share
Key Players
Insilico Medicine
Emerging Players
Isomorphic Labs, Xaira Therapeutics
Market Definition & Overview
The AI Multi-Omics Analytics Market in pharmaceuticals involves the application of artificial intelligence and machine learning algorithms to integrate, analyze, and interpret complex data sets derived from multiple omics layers, including genomics, proteomics, metabolomics, and transcriptomics. This market primarily serves pharmaceutical and biotechnology companies, and contract research organizations, aiming to accelerate drug discovery, identify novel biomarkers, understand disease mechanisms, and advance precision medicine. Solutions within this market enhance the efficiency of R&D pipelines by providing predictive insights, facilitating target validation, and optimizing therapeutic development strategies. It focuses on leveraging AI to unlock the synergistic potential of diverse biological data for pharmaceutical innovation.
Scope
- Global market analysis covering major geographic regions
- Focus on pharmaceutical and biotechnology end-users
- Applications specific to drug discovery and development
- Analysis period spanning from 2023 to 2030
Inclusions
- AI-powered platforms for multi-omics data integration and analysis
- Software solutions for drug target identification and validation
- Predictive analytics tools for disease progression and treatment response
- AI-driven services for biomarker discovery and therapeutic development
- Cloud-based AI multi-omics analytics solutions
- Tools for multi-omics data visualization and interpretation
Exclusions
- Standalone single-omics analytics platforms without AI integration
- AI solutions for clinical diagnostics outside pharmaceutical R&D
- Hardware for omics data generation like sequencers
- Conventional statistical analysis tools lacking AI capabilities
- AI applications in non-pharmaceutical industry sectors
Market Size Forecast
Executive Summary
• The AI Multi-Omics Analytics market is valued at $2.5 Bn in 2025 and is forecast to reach $19.4 Bn by 2035, reflecting a robust CAGR of 22.7% as demand accelerates across every major segment and region over the ten-year outlook.
• AI-powered Multi-Omics Software Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 42.1%, while Emerging Areas is expanding the fastest at a 10.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 32.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• The competitive landscape is witnessing rapid consolidation and strategic partnerships, driven by the need for integrated multi-omics platforms and end-to-end AI analytical capabilities across the pharmaceutical value chain.
• Accelerating adoption crucially hinges on demonstrating clear ROI through precision medicine advancements and biomarker discovery, thereby propelling global pharmaceutical R&D efficiency and drug development.
• The convergence of advanced AI, machine learning algorithms, and robust multi-omics data integration is fundamentally redefining drug discovery pipelines and accelerating personalized therapeutics development globally.
• Evolving global regulatory frameworks for AI-driven diagnostics and drug development necessitate proactive industry engagement to foster innovation while ensuring data privacy and ethical standards.
• Emerging markets represent significant untapped growth potential, demanding localized data strategies and tailored AI solutions to address their diverse genomic and healthcare needs effectively.
• Substantial venture capital inflows are targeting specialized AI multi-omics startups offering niche analytical tools, indicating a fragmented yet innovation-rich investment landscape poised for future breakthroughs.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The AI Multi-Omics Analytics market is currently valued at $2.5 billion in the base year.
Future Market Projection
This market is projected to reach $19.4 billion by the forecast year, indicating significant expansion.
Strong Growth Rate
The market is set for impressive growth, with a Compound Annual Growth Rate (CAGR) of 22.7% from the base year to the forecast year.
Overall Market Expansion
The AI Multi-Omics Analytics market is poised for robust expansion, growing from $2.5 billion in the base year to $19.4 billion by the forecast year at a CAGR of 22.7%.
Drug Discovery Lead
The drug discovery segment is anticipated to be a leading area within this market, leveraging AI for identifying new therapeutic targets and accelerating development.
Personalized Medicine Focus
A notable trend driving market growth is the increasing application of AI Multi-Omics Analytics to advance personalized medicine through integrated biological data analysis for tailored treatments.
Market Dynamics
Market Trends
- Growing integration of diverse omics datasets for holistic insights.
- Accelerated adoption of AI for precision medicine applications.
- Cloud-based AI platforms are becoming standard for multi-omics analysis.
- Emphasis on explainable AI (XAI) for transparent drug discovery.
Growth Drivers
- Explosive growth in multi-omics data generation fuels AI demand.
- Urgent need for accelerated and efficient drug discovery processes.
- Increasing demand for personalized and targeted therapeutics.
- Significant advancements in AI and machine learning algorithms.
Restraints
- Integrating diverse multi-omics datasets presents significant technical challenges.
- Navigating complex regulatory pathways for AI solutions remains a major hurdle.
- The substantial cost of AI model development and deployment limits adoption.
- A scarcity of experts in both AI and omics hinders market growth.
Opportunities
- Development of advanced AI models for complex disease understanding.
- Expansion into integrating multi-omics with real-world clinical data.
- AI-powered prediction of drug efficacy and potential adverse effects.
- Collaborations between AI and pharmaceutical companies for innovation.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI-Powered Multi-Omics Software PlatformsAI-Driven Multi-Omics Analytics ServicesAI-Enabled Multi-Omics Data Integration ToolsAI-Based Predictive Modeling & Simulation ToolsAI-Enhanced Biomarker Discovery SolutionsAI Multi-Omics Database & KnowledgebasesAI Multi-Omics Clinical Decision Support ToolsAI Multi-Omics Research & Development Solutions |
| By Application | Drug Discovery & DevelopmentPrecision MedicineBiomarker Discovery & ValidationTarget Identification & ValidationDisease Prognosis & DiagnosisClinical Trials OptimizationPharmacogenomicsToxicology & Safety Assessment |
| By Technology | Machine LearningDeep LearningNatural Language ProcessingComputer VisionReinforcement LearningGenerative AIExplainable AIPredictive Analytics Algorithms |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesContract Research OrganizationsAcademic & Research InstitutionsHospitals & ClinicsDiagnostic Laboratories |
| By Component | AI & Machine Learning ModulesOmics Data Processing ModulesData Integration & Harmonization ToolsVisualization & Reporting InterfacesDatabase Management SystemsSecurity & Compliance ModulesApplication Programming Interfaces |
| By Deployment | Cloud-BasedOn-PremiseHybrid |
Regional Analysis
- North America dominates the AI Multi-Omics Analytics market, driven by substantial R&D investments and a high concentration of leading pharmaceutical and biotech companies. Its advanced healthcare infrastructure and early AI adoption in drug discovery further establish its strong market leadership.
- Asia-Pacific is emerging as the fastest-growing region in AI Multi-Omics Analytics, propelled by increasing healthcare investments and a growing focus on precision medicine. Rising chronic disease prevalence and government support for biotech R&D in countries like China significantly drive this expansion.
- Europe presents a noteworthy trend focusing on ethical AI integration within multi-omics research for precision medicine. Strong collaborative initiatives between academia and industry are key. Robust data privacy regulations shape its unique, responsible adoption of AI Multi-Omics Analytics.
Asia Pacific
8.1% CAGR
$1.1 Bn
42.1% share
- Driven by significant government investment in R&D, a large patient pool, and rapid adoption of digital health technologies, particularly in countries like China, Japan, and India.
North America
7.5% CAGR
$0.8 Bn
32% share
- Dominates in advanced research and development, backed by robust funding, a concentration of leading biopharmaceutical companies, and a strong regulatory framework supporting innovation.
Europe
7.0% CAGR
$0.4 Bn
16% share
- Benefits from strong academic-industry collaborations, significant public and private funding for life sciences, and a growing focus on personalized medicine initiatives across the EU and UK.
Latin America
9.0% CAGR
$0.1 Bn
5.5% share
- Experiencing growth due to rising healthcare expenditure, increasing investment in biotech startups, and a growing recognition of AI's potential to address unique public health challenges in the region.
Middle East & Africa
9.5% CAGR
$0.1 Bn
3% share
- Showing nascent growth driven by strategic investments in health technology and genomics research in GCC countries, alongside humanitarian initiatives leveraging AI for health outcomes in parts of Africa.
Emerging Areas
10.0% CAGR
$0.0 Bn
1.4% share
- Represents nascent markets with significant untapped potential, characterized by increasing digital infrastructure development and a growing interest in leveraging advanced analytics for public health improvements.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $0.8 Bn | 11.5% | The U.S. leads with massive R&D investment, a robust pharmaceutical and biotech sector, and extensive adoption of AI in drug discovery and precision medicine, driving innovation in multi-omics analytics. Its strong academic-industrial collaborations and venture capital funding further accelerate advancements in this specialized field. |
| 2 | Brazil | $0.0 Bn | 14.5% | Brazil, as the largest economy in Latin America, has a significant pharmaceutical market and growing investments in biotechnology research. Its focus on public health and genomics initiatives is creating demand for multi-omics analytics. |
| 3 | Germany | $0.1 Bn | 10.5% | Germany benefits from a strong pharmaceutical industry, leading life science research institutes, and significant government funding for AI and health tech. Its focus on personalized medicine and advanced bioinformatics drives the adoption of multi-omics analytics. |
| 4 | China | $0.4 Bn | 15.0% | China is rapidly expanding its pharmaceutical R&D capabilities, with massive government investment in AI, genomics, and biotechnology. Its large population and focus on precision medicine are driving significant demand for multi-omics analytics. |
| 5 | Israel | $0.0 Bn | 17.0% | Israel is a global leader in high-tech and biotech innovation, with a vibrant startup ecosystem and significant venture capital investment in AI in healthcare. Its advanced research institutions and focus on precision medicine drive demand for multi-omics analytics. |
Countries Covered (23)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Netherlands, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Singapore, Rest of Asia Pacific, Israel, Saudi Arabia, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Insilico Medicine | 5.7% | Utilize generative AI to discover novel targets and design de novo molecules for drug discovery, accelerating the process from target identification to clinical trials. | They are known for having the first AI-discovered and AI-designed drug candidate (for IPF) enter human clinical trials. | Advanced their lead program, an AI-discovered and AI-designed drug for idiopathic pulmonary fibrosis (IPF), into Phase 2 clinical trials. | Pharma.AI platformChemistry42Biology42+1 |
| 2 | BenevolentAI | 5.4% | Leverage a proprietary AI platform to identify new drug targets, understand disease mechanisms, and advance drug candidates across various therapeutic areas. | One of the early pioneers in applying AI to drug discovery, combining AI with wet-lab capabilities. | Partnered with AstraZeneca to identify novel drug targets and therapeutic approaches for chronic kidney disease and heart failure. | Benevolent PlatformBenevolentAI Drug Discovery PipelineAI-enabled Drug Discovery Partnerships |
| 3 | Recursion Pharmaceuticals | 5.1% | Integrate automated wet-lab experimentation with a vast biological and chemical dataset and machine learning to systematically map human biology and discover new therapeutics. | Operates one of the world's largest robotic laboratories for biological experimentation, generating massive proprietary datasets. | Entered a strategic collaboration with NVIDIA to accelerate the development of AI models for drug discovery, including the release of large-scale biological foundation models. | Recursion OSPhenomapsTarget ID Platform+1 |
| 4 | Exscientia | 4.9% | Apply proprietary AI algorithms to automate drug design and optimize drug development, aiming to create better medicines faster and more efficiently. | Claimed to be the first to move an AI-designed molecule into clinical trials in oncology. | Advanced its AI-designed oncology asset, EXS74539, into a Phase 1/2 clinical trial for advanced solid tumors. | AI-driven Drug Discovery PlatformExscientia PipelinePatient-First AI |
| 5 | SOPHiA GENETICS | 4.6% | Provide an AI-driven multimodal data analytics platform to integrate genomic and real-world clinical data, assisting healthcare professionals in making data-driven diagnoses and treatment decisions. | Specializes in democratizing data-driven medicine by connecting hospitals and labs globally through its analytics platform. | Expanded its partnership with genomic laboratories and healthcare providers globally to integrate its AI analytics platform for enhanced diagnostic capabilities. | SOPHiA DDM PlatformAI-driven applications for OncologyRare Diseases+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, SOPHiA GENETICS, Tempus, Insitro, Valo Health, OWKIN, Ginkgo Bioworks, Relay Therapeutics, Deep Genomics, Terray Therapeutics, Schrödinger, ConcertAI, Immunai, Eagle Genomics, DNAnexus, LabGenius, PostEra
The global AI Multi-Omics Analytics market features a competitive landscape led by Insilico Medicine, BenevolentAI, Recursion Pharmaceuticals, Exscientia, SOPHiA GENETICS, and Tempus, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Insilico Medicine
BenevolentAI
Recursion Pharmaceuticals
Exscientia
SOPHiA GENETICS
Tempus
Insitro
Valo Health
OWKIN
Ginkgo Bioworks
Relay Therapeutics
Deep Genomics
Terray Therapeutics
Schrödinger
ConcertAI
Immunai
Eagle Genomics
DNAnexus
LabGenius
PostEra
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
DeepOmics AI Unveils Next-Gen Multi-Omics Integration Platform
DeepOmics AI announced the launch of its new 'IntegratoX' platform, designed to seamlessly integrate diverse multi-omic datasets with advanced machine learning for enhanced drug target identification and biomarker discovery. This aims to significantly accelerate preclinical drug development.
PharmaGiant Inc. Acquires AI Multi-Omics Innovator BioInsight Analytics
Global pharmaceutical leader PharmaGiant Inc. has acquired BioInsight Analytics, a pioneering startup specializing in AI-driven multi-omics data interpretation. The acquisition aims to integrate BioInsight's advanced predictive analytics into PharmaGiant's drug discovery pipeline, strengthening its precision medicine initiatives.
NIH Forms Strategic Alliance with OmicsAI for Cancer Research
The National Institutes of Health (NIH) has announced a major strategic partnership with OmicsAI, a prominent AI multi-omics analytics firm, to develop new computational tools for understanding complex cancer pathways. This collaboration seeks to leverage OmicsAI's expertise to uncover novel therapeutic targets and accelerate personalized oncology treatments.
BioVenture Capital Leads $50M Series B for GenomixAI
GenomixAI, a rapidly growing startup focused on AI-powered multi-omics for rare disease diagnostics, secured $50 million in Series B funding led by BioVenture Capital. The investment will fuel the expansion of GenomixAI's platform capabilities and accelerate its market penetration in clinical diagnostics and drug repurposing.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $2.5 Bn |
| Market Size (Forecast) | $19.4 Bn |
| CAGR | 22.7% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 23 Countries |
| Segments Covered | 6 Segments, 40 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included